TYK2 inhibition and its potential in the treatment of chronic inflammatory immune diseases.
Journal
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
ISSN: 1610-0387
Titre abrégé: J Dtsch Dermatol Ges
Pays: Germany
ID NLM: 101164708
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
received:
28
10
2020
accepted:
08
06
2021
pubmed:
29
9
2021
medline:
10
11
2021
entrez:
28
9
2021
Statut:
ppublish
Résumé
Immune-mediated chronic inflammatory diseases have emerged as a leading cause of morbidity and mortality in Western countries over the last decades. Although multiple putative factors have been suspected to be causally related to the diseases, their overarching etiology remains unknown. This review article summarizes the current state of scientific knowledge and understanding of the role of non-receptor tyrosine kinases, with a special focus on the Janus kinase TYK2 in autoimmune and immune mediated diseases as well as on the clinical properties of its inhibition. A panel of experts in the field discussed the scientific evidence and molecular rationale for TYK2 inhibition and its clinical application. Reviewing this meeting, we aim at providing an integrated overview of the clinical profile of TYK2 inhibition and its potential in targeted pharmacological therapy of chronic autoimmune and immune-mediated diseases, with a special focus on inflammatory diseases of the skin.
Substances chimiques
TYK2 Kinase
EC 2.7.10.2
TYK2 protein, human
EC 2.7.10.2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1409-1420Informations de copyright
© 2021 The Authors. Journal der Deutschen Dermatologischen Gesellschaft published by John Wiley & Sons Ltd on behalf of Deutsche Dermatologische Gesellschaft.
Références
El-Gabalawy H, Guenther LC, Bernstein CN. Epidemiology of immune-mediated inflammatory diseases: incidence, prevalence, natural history, and comorbidities. J Rheumatol Suppl 2010; 85: 2-10.
Annunziato F, Romagnani C, Romagnani S. The 3 major types of innate and adaptive cell-mediated effector immunity. J Allergy Clin Immunol 2015; 135(3): 626-35.
Feuchtenberger M, Kneitz C, Tony H. Zytokine. Z. Rheumatol 2007; 66: 297-303.
Murphy KM, Travers P, Walport M. Janeway Immunologie, 7. Aufl., Springer, 2014: 817-91.
Nast A, Amelunxen L, Augustin M et al. S3 Guideline for the treatment of psoriasis vulgaris, update - Short version part 1 - Systemic treatment. J Dtsch Dermatol Ges 2018; 16(5): 645-69.
Ghoreschi K, Balato A, Enerbäck C, Sabat R. Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. Lancet 2021; 397(10275): 754-66.
Feldman SR, Holmen Moeller A, Erntoft Idemyr ST, González JM. Relative importance of mode of administration in treatment preferences among plaque psoriasis patients in the United States. JHEOR 2016; 4(2): 141-57.
Fernández-Clotet A, Castro-Poceiro J, Panés J. JAK Inhibition: The most promising agents in the IBD pipeline? Curr Pharm Des 2019; 25(1): 32-40.
Ghoreschi K, Laurence A, O’Shea JJ. Janus kinases in immune cell signaling. Immunol Rev 2009; 228(1): 273-87.
Firmbach-Kraft I, Byers M, Shows T et al. Tyk2, prototype of a novel class of non-receptor tyrosine kinase genes. Oncogene 1990; 5(9): 1329-36.
Strange A, Capon F, Spencer CCA et al. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet 2010; 42(11): 985-90.
Franke A, McGovern DP, Barrett JC et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn’s disease susceptibility loci. Nat Genet 2010; 42(12): 1118-25.
Gorman JA, Hundhausen C, Kinsman M et al. The TYK2-P1104A autoimmune protective variant limits coordinate signals required to generate specialized T cell subsets. Front Immunol 2019; 10: 44.
Coskun M, Salem M, Pedersen J, Nielsen OH. Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease. Pharmacol Res 2013; 76: 1-8.
Ghoreschi K, Laurence A, Yang XP et al. Generation of pathogenic T(H)17 cells in the absence of TGF-β signalling. Nature 2010; 467(7318): 967-71.
O’Shea JJ, Murray PJ. Cytokine signaling modules in inflammatory responses. Immunity 2008; 28(4): 477-87.
Lauffer F, Eyerich K, Boehncke WH et al. Cytokines of the IL-17 family in psoriasis. J Dtsch Dermatol Ges 2020; 18: 675-81.
Harden JL, Krueger JG, Bowcock AM. The immunogenetics of psoriasis: A comprehensive review. J Autoimmun 2015; 64: 66-73.
Hodge JA, Kawabata TT, Krishnaswami S et al. The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin Exp Rheumatol 2016; 34(2): 318-28.
Minegishi Y, Saito M, Morio T et al. Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity 2006; 25(5): 745-55.
Welsch K, Holstein J, Laurence A, Ghoreschi K. Targeting JAK/STAT signalling in inflammatory skin diseases with small molecule inhibitors. Eur J Immunol 2017; 47(7): 1096-107.
Solimani F, Meier K, Ghoreschi K. Emerging topical and systemic JAK inhibitors in dermatology. Front Immunol 2019; 10: 2847.
Ghoreschi K, Laurence A, O’Shea JJ. Selectivity and therapeutic inhibition of kinases: to be or not to be? Nat Immunol 2009; 10(4): 356-60.
Forster M, Chaikuad A, Bauer SM et al. Selective JAK3 inhibitors with a covalent reversible binding mode targeting a new induced fit binding pocket. Cell Chem Biol 2016; 23(11): 1335-40.
Forster M, Chaikuad A, Dimitrov T et al. Development, optimization, and structure-activity relationships of covalent-reversible JAK3 inhibitors based on a tricyclic imidazo[5,4- d]pyrrolo[2,3- b]pyridine scaffold. J Med Chem 2018; 61(12): 5350-66.
Tokarski JS, Zupa-Fernandez A, Tredup JA et al. Tyrosine kinase 2-mediated signal transduction in T lymphocytes is blocked by pharmacological stabilization of its pseudokinase domain. J Biol Chem 2015; 290(17): 11061-74.
Catlett I, Aras U, Liu Y et al. SAT0226: A first-in-human, study of BMS-986165, a selective, potent, allosteric small molecule inhibitor of tyrosine kinase 2. Ann Rheum Dis 2017; 76: 859.
Papp K, Gordon K, Thaçi D et al. Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis. N Engl J Med 2018; 379(14): 1313-21.
Wrobleski ST, Moslin R, Lin S et al. Highly selective inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS-986165. J Med Chem 2019; 62: 8973-95.
Nogueira M, Puig L, Torres T. JAK inhibitors for treatment of psoriasis: Focus on selective TYK2 inhibitors. Drugs 2020; 80(4): 341-52.
Ma C, Lee JK, Mitra AR et al. Systematic review with meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease. Aliment Pharmacol Ther 2019; 50: 5-23.
Harigai M. Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis. Rheumatology (Oxford) 2019; 58 (suppl 1): i34-42.
Alinaghi F, Calov M, Kristensen LE et al. Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol 2019; 80(1): 251-265.e19.
Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med 2017; 376(10): 957-970. Erratum in: N Engl J Med 2017; 376(21): 2097.
Mease PJ, Armstrong AW. Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. Drugs 2014; 74(4): 423-41.
Ryser C, Ciurea A. Therapie der Psoriasisarthritis unter Berücksichtigung neuer Behandlungsoptionen. Praxis 2018; 107(21): 1147-53.
Tesmer LA, Lundy SK, Sarkar S, Fox DA. Th-17 cells in human disease. Immunol Rev 2008; 223: 87-113.
Yago T, Nanke Y, Kawamoto M et al. IL-23 and Th-17 disease in inflammatory arthritis. J Clin Med 2017; 6(9): 81.
Amarasekara DS, Yun H, Kim S et al. Regulation of osteoclast differentiation by cytokine networks. Immune Netw 2018; 18(1): e8
Thaci D, Papp K, Gordon KB et al. Efficacy of tyrosine kinase 2 (TYK2) inhibition in immune-mediated diseases with an oral, selective TYK2 inhibitor, BMS-986165. 47. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh), 33. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh), 29. Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR) 2019; Meeting Abstract.
Sieper J, Rudwaleit M, Baraliakos X et al. The assessment of SpondyloArthritis International Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis 2009; 68(Suppl 2): ii1-ii44.
Gracey E, Hromadová D, Lim M et al. TYK2 inhibition reduces type 3 immunity and modifies disease progression in murine spondyloarthritis. J Clin Invest 2020; 130(4): 1863-78.
Taurog JD, Chhabra A, Colbert RA. Ankylosing spondylitis and axial spondyloarthritis. N Engl J Med 2016; 374(26): 2563-74.
Virtanen A, Haikarainen T, Raivola J, Silvennoinen O. Selective JAKinibs: Prospects in inflammatory and autoimmune diseases. BioDrugs 2019; 33(1): 15-32.
Mohammadi S, Sedighi S, Memarian A. IL-17 is Aberrantly overexpressed among under-treatment systemic lupus erythematosus patients. Iran J Pathol 2019; 14(3): 236-42.
Annese V, Beaugerie L, Egan L et al. European evidence-based consensus: Inflammatory bowel disease and malignancies. J Crohns Colitis 2015; 9(11): 945-65.
Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 2011; 140(6): 1785-94.
Graham DB, Xavier RJ. Pathway paradigms revealed from the genetics of inflammatory bowel disease. Nature 2020; 578(7796): 527-39.
Kaser A, Zeissig S, Blumberg RS. Inflammatory bowel disease. Annu Rev Immunol 2010; 28: 573-621.
ten Hove T, van Montfrans C, Peppelenbosch MP, van Deventer SJ. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn’s disease. Gut 2002; 50(2): 206-11.
Neurath, MF. Targeting immune cell circuits and trafficking in inflammatory bowel disease. Nat Immunol 2019; 20: 970-9.
Atreya R, Neurath MF. Mechanisms of molecular resistance and predictors of response to biological therapy in inflammatory bowel disease. Lancet Gastroenterol Hepatol 2018; 3(11): 790-802.
Gillooly K, Zhang Y, Yang X et al. BMS-986165 is a highly potent and selective allosteric inhibitor of Tyk2, blocks IL-12, IL-23 and type I interferon signaling and provides for robust efficacy in preclinical models of systemic lupus erythematosus and inflammatory bowel disease [abstract]. Arthritis Rheumatol 2016; 68 (suppl 10).
Xie JH, Gillooly K, Zhang Y et al. BMS-986165 is a highly potent and selective allosteric inhibitor of TYK2, blocks Il-12, IL-23 and type I interferon signaling and provides for robust efficacy in preclinical models of inflammatory bowel disease [abstract]. DDW Abstracts 2018; 154 (6/Supplement 1): 1357.
Kim DH, Cheon JH. Pathogenesis of inflammatory bowel disease and recent advances in biologic therapies. Immune Netw 2017; 17(1): 25-40.
Marafini I, Sedda S, Dinallo V, Monteleone G. Inflammatory cytokines: from discoveries to therapies in IBD. Expert Opin Biol Ther 2019; 19(11): 1207-17.
Kahn JS, Deverapalli SC, Rosmarin DM. JAK-STAT signaling pathway inhibition: A role for treatment of discoid lupus erythematosus and dermatomyositis. Int J Dermatol 2018; 57(8): 1007-14.
You H, Xu D, Zhao J et al. JAK Inhibitors: Prospects in connective tissue diseases [published online ahead of print, 2020 Mar 28]. Clin Rev Allergy Immunol 2020 https://doi.org/10.1007/s12016-020-08786-6.
Alves de Medeiros AK, Speeckaert R, Desmet E et al. JAK3 as an emerging target for topical treatment of inflammatory skin diseases. PLoS One 2016; 11(10): e0164080.
Méndez-Flores S, Hernández-Molina G, Enríquez AB et al. Cytokines and effector/regulatory cells characterization in the physiopathology of cutaneous lupus erythematous: A cross-sectional study. Mediators Inflamm 2016; 2016: 7074829.